Growth Has To Clear More Than One Gate
The strongest growth stories often look nothing alike. One of today’s candidates supplies the infrastructure behind programmatic streaming advertising. The other is trying to turn a new form of gene editing into one-time therapies. What they share is a combination of improving evidence, technical confirmation and an options structure that gives the thesis time to work without leaving the downside undefined.
The first candidate’s latest quarter showed accelerating connected-TV activity, expanding profitability and higher full-year guidance. The second has regulatory and clinical milestones extending through 2027. Both sit in our preferred RSI range, and the first candidate also passes our “Really Time To Buy?” screen, giving us a second, independent reason to include it here.
Different Risks Need Different Structures
The established business gets a hybrid structure extending through two more earnings reports. A nearer-dated short call and a defined-risk put spread finance the March call while keeping maximum risk near our usual budget.
The biotech is a retry from Monday’s alert, where our order didn’t fill. This time, we’re using a two-to-one call ratio: four capped call spreads paired with four additional calls. The structure eliminates the short puts from the earlier attempt, limits the loss to the premium paid and preserves uncapped participation if the clinical platform delivers.
Both option markets are wide, so price discipline matters. Paid subscribers will find the names, complete structures, maximum entry prices and initial exit plans below.
Today’s Chartmill Trade
Programmatic streaming and connected-TV advertising theme.
RSI: 58; Chartmill Technical Rating: 9; Setup Rating: 7; Fundamental Rating: 5.
